MedTrace Logo

Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

NCT00820690 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2015-08-05

No results posted yet for this study

Summary

The purpose of this study is to analyze gene expression signature and immunohistochemical markers associated with clinical and pathological response to neoadjuvant chemotherapy in locally advanced breast cancer.

Conditions

Interventions

DRUG

doxorubicin

4 cycles AC: doxorubicin 60mg/m2

DRUG

cyclophosphamide

4 cycles AC: cyclophosphamide 600mg/m2

DRUG

paclitaxel

4 cycles T: paclitaxel 175mg/m2 after 4 AC

PROCEDURE

Surgery

The surgery will be performed 30 days after the chemotherapy. The correlation between clinical, radiologic and pathologic response will be reported. The oncoplastic surgery rate will be reported

Sponsors & Collaborators

  • University of Sao Paulo

    collaborator OTHER

  • Barretos Cancer Hospital

    lead OTHER

Principal Investigators

  • Maria Aparecida A Koike Folgueira, MD, PhD · Faculdade de Medicina - Universidade de São Paulo

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2012-04-30
Completion
2017-09-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00820690 on ClinicalTrials.gov